These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 11467310)

  • 21. Effect of repaglinide, administered two or three times daily for 3 months, on glycaemic control in Japanese patients with type 2 diabetes mellitus.
    Kamiyama H; Aoki K; Nakajima S; Shinoda K; Kamiko K; Taguri M; Terauchi Y
    J Int Med Res; 2014 Oct; 42(5):1150-60. PubMed ID: 25015763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Repaglinide induced acute hepototoxicity.
    Jaiswal S; Mehta R; Musuku M; Tran L; McNamee W
    JNMA J Nepal Med Assoc; 2009; 48(174):162-4. PubMed ID: 20387361
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treating type 2 diabetes. When diet and exercise aren't enough, a broad range of medications can help control our blood sugar.
    Blackburn GL
    Health News; 2004 Aug; 10(8):4-5. PubMed ID: 15551454
    [No Abstract]   [Full Text] [Related]  

  • 24. [Flexible oral therapy of diabetes mellitus type 2: dietary glucose regulation as therapeutic principle. 34th annual session of the European Association for the Study of Diabetes (EASD). Barcelona, 8-12 September 1998].
    Dtsch Med Wochenschr; 1998 Dec; 123(50 Suppl Flexible):1-4. PubMed ID: 9883267
    [No Abstract]   [Full Text] [Related]  

  • 25. [Repaglinide (NN-623)].
    Matsuda M; Kaku K
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():555-8. PubMed ID: 12387050
    [No Abstract]   [Full Text] [Related]  

  • 26. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function.
    Hasslacher C;
    Diabetes Care; 2003 Mar; 26(3):886-91. PubMed ID: 12610054
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insulin requirement after one year of insulin therapy in type 2 diabetic patients dependent on fasting C-peptide.
    Biesenbach G; Bodlaj G; Pieringer H; Raml A
    Neth J Med; 2008 Jun; 66(6):259-60. PubMed ID: 18689911
    [No Abstract]   [Full Text] [Related]  

  • 28. Effects of nateglinide and repaglinide administered intracerebroventricularly on the CA3 hippocampal neuronal cell death and hyperglycemia induced by kainic acid in mice.
    Kim CH; Park SH; Sim YB; Kim SS; Kim SJ; Lim SM; Jung JS; Suh HW
    Brain Res Bull; 2014 May; 104():36-41. PubMed ID: 24704461
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Meal-induced platelet activation in Type 2 diabetes mellitus: effects of treatment with repaglinide and glibenclamide.
    Yngen M; Ostenson CG; Hjemdahl P; Wallén NH
    Diabet Med; 2006 Feb; 23(2):134-40. PubMed ID: 16433710
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [symbol: see text] Nateglinide and [symbol: see text] repaglinide for type 2 diabetes?
    Drug Ther Bull; 2003 Jul; 41(7):52-4. PubMed ID: 12879789
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Type 2 diabetes management.
    Nelson G
    Br J Community Nurs; 2002 Jan; 7(1):5. PubMed ID: 11823724
    [No Abstract]   [Full Text] [Related]  

  • 32. Prolonged hypoglycemia after a suicidal ingestion of repaglinide with unexpected slow plasma elimination.
    Elling R; Spehl MS; Wohlfarth A; Auwaerter V; Hermanns-Clausen M
    Clin Toxicol (Phila); 2016; 54(2):158-60. PubMed ID: 26692235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized controlled trial examining combinations of repaglinide, metformin and NPH insulin.
    Davies MJ; Thaware PK; Tringham JR; Howe J; Jarvis J; Johnston V; Kitchener DL; Skinner TC; McNally PG; Lawrence IG
    Diabet Med; 2007 Jul; 24(7):714-9. PubMed ID: 17403126
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Therapy of type 2 diabetes. Avoiding postprandial blood glucose peaks!].
    MMW Fortschr Med; 2001 Oct; 143(40):55. PubMed ID: 11692849
    [No Abstract]   [Full Text] [Related]  

  • 35. [News in oral antidiabetic therapy].
    Pospísilová Y
    Vnitr Lek; 2001 Sep; 47(9):627-33. PubMed ID: 11715668
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical experience with repaglinide in patients with non-insulin-dependent diabetes mellitus.
    Shapiro MS; Abrams Z; Lieberman N
    Isr Med Assoc J; 2005 Feb; 7(2):75-7. PubMed ID: 15729954
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The combination oral and nutritional treatment of late-onset diabetes mellitus (CONTROL DM) trial results.
    Reboussin DM; Goff DC; Lipkin EW; Herrington DM; Summerson J; Steffes M; Crouse RJ; Jovanovic L; Feinglos MN; Probstfield JL; Banerji MA; Pettitt DJ; Williamson J
    Diabet Med; 2004 Oct; 21(10):1082-9. PubMed ID: 15384954
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic profiles of repaglinide in elderly subjects with type 2 diabetes.
    Hatorp V; Huang WC; Strange P
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1475-8. PubMed ID: 10199798
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of costs for four oral antidiabetic regimens within a managed care population.
    Stockl K; Vanderplas AM; Nicklasson L
    Manag Care Interface; 2003 Jul; 16(7):31-6. PubMed ID: 12908215
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cholestatic hepatitis associated with repaglinide.
    López-García F; Borrás J; Verdú C; Salazar VR; Ruiz JA; Sales J; Lucena MI; Andrade RJ
    Diabetes Care; 2005 Mar; 28(3):752-3. PubMed ID: 15735221
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.